pathogen

1) The skin barrier is weaker and drier.
Healthy skin is a tidy, water-holding barrier made of closely packed cells and oily lipids. In eczema that barrier is “leaky”: it loses moisture faster (higher transepidermal water loss), is physically drier, and the outer layer cracks or flakes more easily. Those cracks and gaps expose proteins and sugars deep in the skin that are normally hidden — and those exposed molecules act like handholds for bacteria.

2) S. aureus can stick and settle.
Staphylococcus aureus has surface proteins that recognize and bind to the exposed skin molecules. Once it latches on it’s much harder for the bacteria to be removed by normal rubbing or washing. In some cases the bacteria form biofilms — slimy communities that cling to the surface — which further helps them persist.

3) The skin’s chemical defenses are reduced.
Healthy skin makes natural antimicrobial peptides (AMPs) — small proteins (sometimes called the skin’s “antibiotics”) such as defensins and cathelicidins — that directly kill or slow bacteria. Eczema skin produces fewer of these AMPs, so there’s less biochemical resistance to bacterial growth. Put simply: there are fewer guards on duty.

4) Inflammation and scratching make things worse.
Eczema causes itching and inflammation. Scratching spreads bacteria across the skin surface and can create tiny breaks or wounds. Those micro-injuries are perfect entry points and new places for S. aureus to colonize and multiply. Inflammation itself changes the local environment (pH, nutrients, immune signals) in ways that can favor the bacteria.

5) The result: overgrowth, not a new “infection” from outside.
Because of the leaky barrier, fewer antimicrobial peptides, and ongoing inflammation and scratching, the skin becomes an environment where S. aureus can overgrow and dominate. That’s why people with eczema don’t usually “catch” S. aureus in the sense of a new external infection — rather, the bacteria that are commonly present on everyone’s skin or in the environment are able to expand on eczema-affected skin while healthy skin keeps their numbers low.

Short summary / analogy:
Think of healthy skin as a well-sealed house with locks and security lights (tight barrier + antimicrobial peptides). Eczema is like a house with broken windows and no lights: it’s easier for unwanted guests (S. aureus) to get inside, stay, and throw a noisy party.

A few important layers you could add, depending on how complete you want this to be. None of these contradict what you already wrote; they just deepen it.

1) Microbiome imbalance (not just one bacterium)
Healthy skin has a diverse microbiome where different microbes keep each other in check. In eczema, that diversity drops, and S. aureus crowds out other, more neutral or protective bacteria. Once it dominates, it actively makes the skin inflammation worse, which then further damages the barrier — a self-reinforcing loop.

2) Toxins and immune overstimulation
S. aureus doesn’t just sit there — it releases toxins and “superantigens” that overstimulate the immune system. These molecules can directly worsen redness, itching, and swelling, even without a classic infection. This helps explain why eczema flares often calm down when S. aureus levels are reduced, even if there was no obvious pus or infection.

3) Skin pH changes
Eczema skin often has a higher (less acidic) pH. Healthy, slightly acidic skin discourages S. aureus growth and supports antimicrobial peptides. When pH rises, AMPs work less well and S. aureus grows more easily — another subtle but important advantage for the bacteria.

4) Barrier proteins are altered
Many people with eczema have reduced or abnormal filaggrin and related barrier proteins. This weakens the structure of the outer skin layer and changes how skin cells mature, again exposing binding sites that S. aureus prefers.

5) The vicious cycle framing
It can help to explicitly state that this is a loop:

• Barrier damage → bacterial overgrowth

• Bacterial toxins → more inflammation and itching

• Scratching → more barrier damage

• Weaker defenses → even more bacterial dominance

Once that cycle is established, S. aureus isn’t just a passenger — it becomes an active driver of the disease.

6) Why this matters clinically
Adding one sentence on implications can strengthen the explanation:

This is why eczema treatment isn’t only about killing bacteria, but about restoring the skin barrier, reducing inflammation, and rebalancing the skin environment — otherwise S. aureus quickly returns.

(Source : ChatGPT)

Eczema (atopic dermatitis) is best understood today as a condition where three things meet and feed each other: an imperfect skin barrier, an over-reactive immune system, and changes in the microbes that live on the skin. The idea that bacteria play a meaningful role in eczema did not come all at once; it grew out of many observations over decades. The very bacteria most often implicated, staphylococci, were first described in pus by Alexander Ogston in the 1880s, which established that these microbes were common inhabitants and causes of skin infections long before eczema itself was studied in molecular detail. (CDC)

By the 1970s clinicians and microbiologists were noticing a striking pattern: inflamed eczema skin is frequently crowded with a single species, Staphylococcus aureus. In a widely cited paper from the mid-1970s, J. J. Leyden and colleagues showed that S. aureus was present at much higher numbers on eczema lesions than on healthy skin, and follow-up studies in the 1980s confirmed higher carriage and density of the bacterium on both lesional and apparently normal skin of people with atopic dermatitis. Those clinical microbiology findings shifted thinking from “eczema is only an immune or allergic disease” to a model in which microbes help drive flares. (PubMed)

Laboratory work over the next decades explained how the bacteria make things worse. Certain strains of S. aureus produce a mix of molecules — toxins, enzymes and so-called superantigens — that directly damage skin cells, break down the barrier, and powerfully stimulate immune cells. Some toxins punch holes in keratinocytes (the main skin cells), other proteins act like potent signals that make immune cells release inflammatory chemicals, and proteases can expose nerve endings that produce intense itch. Together, these bacterial products turn a vulnerable patch of skin into a site of escalating inflammation. Reviews and experimental studies over the 1990s–2020s summarized and confirmed these mechanisms. (PMC)

At the same time, genetic discoveries clarified why some people are more vulnerable in the first place. A landmark 2006 genetics paper led by Colin N. A. Palmer and collaborators showed that loss-of-function mutations in the gene for filaggrin — a protein that helps form and hydrate the outer layer of skin — are a major risk factor for developing atopic dermatitis. People with filaggrin defects have a weaker barrier, so irritants and microbes get in more easily; that helps explain why the bacterial overgrowth pattern is so common in eczema. The filaggrin discovery shifted research and treatment emphasis toward protecting and repairing the skin barrier, not only suppressing inflammation. (PubMed)

More recently, DNA sequencing and careful sampling have shown that S. aureus doesn’t just passively sit on eczematous skin: particular strains adapt to the inflamed environment, acquire mutations, and express genes that increase their capacity to stick, make toxins, and survive the local conditions. Genomic studies and microevolution analyses in the 2010s and 2020s have mapped those changes and made it clear that the interaction between host (skin + immune system) and bacteria is dynamic — the skin environment shapes the bacteria and the bacteria shape the immune response. (news.mit.edu)

All this history explains why modern treatments take a mixed approach. Restoring the barrier (moisturizers, emollients), calming the over-active immune response when needed (topical steroids or newer targeted drugs), and reducing the harmful activity of bacteria (short courses of antibiotics in some cases, antiseptic washes, or newer anti-virulence strategies) can all be useful — and they work best when combined thoughtfully. One recent innovation, developed by researchers at The University of Hong Kong, is a plant-based moisturizer called Anesinin that aims to “tame” S. aureus by suppressing the bacteria’s toxin production rather than killing the bacteria outright; this is an application of the anti-virulence idea that emerged from the biological studies described above. Early reports are promising but larger clinical trials and peer-reviewed data will be needed to know how broadly and durably such products help. (tech-transfer.med.hku.hk)

In short, eczema is not a simple autoimmune attack but a condition where a weak skin barrier, a sensitized immune system, and sometimes opportunistic bacteria together create a self-reinforcing loop of itch, inflammation and barrier breakdown. The historical arc — from Ogston’s 19th-century description of staphylococci through the 1970s clinical associations, the 2006 filaggrin genetics breakthrough, and the genomics and mechanistic studies of recent years — shows how the field moved from seeing eczema as purely “immune” to seeing it as an ecosystem problem in which bacteria can be important drivers.

(Source : ChatGPT)

In a study published in PNAS, scientists reveal that the survival of the bacterium responsible for tuberculosis, Mycobacterium tuberculosis, depends on a specialized transporter that enables it to absorb sulfate, a mineral form of sulfur. This transporter is highly specific to M. tuberculosis and could therefore be a target for drugs without side effects on human cells.

Tuberculosis, still a formidable enemy

Tuberculosis remains one of the deadliest infectious diseases today. Each year, it affects millions of people worldwide and continues to claim many lives, despite the existence of a vaccine and available treatments. In 2023, the World Health Organization reported 10.8 million new cases. The situation is further complicated by the emergence of antibiotic-resistant strains: these bacteria evade current treatments—which are already lengthy and difficult to follow—making the search for new solutions more urgent than ever.

Understanding the bacterium’s lifestyle to fight it more effectively

Tuberculosis is caused by a bacterium known as Mycobacterium tuberculosis. To combat it effectively, it is essential to understand its way of life. How does it survive inside the human body? How does it hijack our immune defenses to its own advantage? And above all, what mechanisms allow it to persist for years in a dormant state before reactivating to cause disease? These are the fundamental questions that a team of French scientists set out to address—leading to a major breakthrough published in the journal PNAS.
A discovery about the bacterium’s sulfur intake

For a long time, the scientific community believed that the bacterium fed mainly on organic sulfur, particularly from methionine, an amino acid taken directly from our cells. But this study overturns that view: the scientists show that M. tuberculosis actually prefers to import “inorganic” sulfate—a form of sulfur present in our bodies—through a specialized transporter named SubI-CysTWA.
To reach this conclusion, they used a highly precise imaging technology called NanoSIMS, which makes it possible to visualize chemical elements—including sulfur—directly within the cells infected by the bacterium. They observed that the bacterium stores large amounts of sulfur derived from sulfate, especially when it is in full activity.

The SubI transporter is required for sulfate import in intracellular bacteria.

The bacteria (M. tuberculosis) were cultured in the presence of glucose labeled with the isotope ¹³C to allow visualization within infected macrophages (left panels). The cells were incubated with sulfate labeled with ³³S in order to track the molecule inside infected cells (right panels). The cells were infected either with wild-type bacteria (top panels) or with a mutant lacking an active SubI transporter (bottom panels). The figure shows sulfate accumulation in the wild-type bacteria, but not in those that do not express the transporter.

A weak point to exploit for future treatments

The scientists then inactivated the gene responsible for producing this transporter. The result: the growth of the bacterium in laboratory cultures slowed down, and its survival decreased in the lungs of infected mice. It also became more sensitive to oxidative stress—a natural reaction of our defenses against pathogens.
This dependency is particularly interesting because the SubI-CysTWA transporter exists only in M. tuberculosis. Drugs targeting this mechanism could therefore weaken the bacterium without harming human cells. Such an approach could also boost the effectiveness of antibiotics already in use, such as isoniazid, and help shorten treatment duration.

A promising breakthrough

In a context where current treatments are lengthy and resistance is on the rise, this discovery opens a new avenue: blocking access to sulfate to prevent the bacterium from defending itself. In the long term, this could improve treatment efficacy, limit resistance, and ultimately save many lives.

(Source : Institute of Biology Paris-Seine)

The molecules trigger a built-in cellular stress response and show promise as broad-spectrum antivirals against Zika, herpes, RSV, and more.

Researchers at MIT and other institutions have identified compounds that can fight off viral infection by activating a defense pathway inside host cells. These compounds, they believe, could be used as antiviral drugs that work against not just one but any kind of virus.

The researchers identified these compounds, which activate a host cell defense system known as the integrated stress response pathway, in a screen of nearly 400,000 molecules. In tests in human cells, the researchers showed that the compounds help cells fend off infection from RSV, herpes virus, and Zika virus. They also proved effective in combating herpes infection in a mouse model.

The research team now plans to test the compounds against additional viruses, in hopes of developing them for eventual clinical trials.

“We’re very excited about this work, which allows us to harness the stress response of the host cells to arrive at a means to identify and develop broad-spectrum antivirals,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering.

Collins and Maxwell Wilson, an associate professor of molecular biology at the University of California, Santa Barbara and chief scientific officer of Integrated Biosciences, are the senior authors of the new study, which appears in Cell. Felix Wong, a former MIT postdoc and chief executive officer of Integrated Biosciences, is the lead author of the paper. In addition to MIT, UCSB, and Integrated Biosciences, the research team also includes scientists from Illumina Ventures and Princeton University.

Boosting cell defense

In human cells, the integrated stress response pathway is turned on in response to viral infection as well as other types of stress such as starvation. During viral infection, the pathway is triggered by double-stranded RNA, a molecule produced during the replication cycle of viruses. When that RNA is detected, the cell shuts down protein synthesis, which blocks the virus from producing the proteins it needs to replicate.
Compounds that boost this pathway, the researchers believe, could be good candidates for new antiviral drugs that could combat any type of virus.

“Typically, how antivirals are developed is that you develop one antiviral for one specific virus,” Wong says. “In this case, we hypothesized that being able to modulate the host cell stress response might give us a new class of broad-spectrum antivirals — compounds that directly act on the host cells to alter something fundamental about how all viruses replicate.”

To help them identify compounds that would enhance the activity of this pathway during viral infection, the researchers invented a novel optogenetic screen. Optogenetics is a bioengineering technique that allows researchers to insert light-sensitive proteins into the genome of a cell. In this case, the researchers engineered modifications to a protein called PKR, which turns on the stress pathway, so that they could turn it on with light.

Using this technique, the researchers screened a library of nearly 400,000 commercially available and proprietary chemical compounds. Each of these compounds was applied to human cells as the cells were also exposed to blue light, which simulated viral infection by activating PKR.

By measuring the cells’ survival rates, the researchers could determine which compounds boosted activation of the pathway and amplified the cells’ ability to shut down viral reproduction. This screen yielded about 3,500 compounds with potential antiviral activity, which were evaluated further.

“If the pathway were turned on in response to viral infection, what our compounds do is they turn it on full blast,” Wong says. “Even in the presence of a small amount of virus, if the pathway is triggered, then the antiviral response is also maximized.”

Fighting infection

The researchers then selected eight of the most promising compounds and screened them for their ability to kill viruses while avoiding harmful effects in human cells. Based on these tests, the researchers chose three top candidates, which they called IBX-200, IBX-202, and IBX-204.

In cells that were infected with either Zika virus, herpes virus, or RSV, treatment with these compounds significantly reduced the amount of virus in the cells. The researchers then tested one of the compounds, IBX-200, in mice infected with herpes virus, and found that it was able to reduce the viral load and improve symptoms.

Experiments showed that these compounds appear to turn on an enzyme that is involved in detecting stress. This activates the stress response pathway and primes the cells to become more responsive to viral infection. When applied to cells that are not already infected, the compounds have no effect.

The researchers now plan to evaluate their lead candidates against a broader range of viruses. They also aim to identify additional compounds that activate the integrated stress response, as well as other cellular stress pathways with the potential to clear viral or bacterial infections.

The research was funded by the Defense Threat Reduction Agency, the National Science Foundation, the U.S. Army Research Office, and Integrated Biosciences.

(Source : MITNews)